Business Weekly - Cambridge, UK
Archive Life Sciences Archive CeNeS' sedative showing promise | CeNeS' sedative showing promise |
| Written by Business Weekly | |
| Thursday, 21 June 2007 | |
|
Cambridge biopharmaceutical firm, CeNeS has reported promising data on its short-acting sedative, CNS 7056 and said it plans to file an IND and commence Phase I trials in the coming months.
The pain treatment specialist said that CNS 7056 had produced promising results in a pre-clinical trial, “inducing deep sedation rapidly and controllably, with predictable effects over a wide range of doses and a rapid recovery.” The compound will be developed for the induction and maintenance of anaesthesia in addition to sedation for day-case procedures, CeNeS said. CEO, Neil Clark said: “Development for the additional indications of the induction and maintenance of anaesthesia means that the market potential is significantly larger.” “We believe that the peak sales opportunity for this compound is now doubled to £400m. We are looking forward to filing an IND for this compound in the next few months and commencing Phase I clinical trials.” Shares in the firm remain unchanged at 5.125p. |
| < Prev | Next > |
|---|
|
Featured business directory listing
 SDC Systems www.sdcsystems.com Category: Electronics |
Site Login
Advertisement
 |